CRISPR-based mouse model for VHL-deficient clear cell kidney cancer shows promise, suggested by Yüksel Ürün

Yüksel Ürün shared an article by Laura A Stransky on X:

“A new CRISPR-based mouse model for VHL-deficient clear cell kidney cancer shows promise.

Though not fully HIF2-dependent, challenges remain in mimicking human tumor behavior at PNAS News, Kaelin Lab, Signoretti Lab, Dana-Farber Cancer Institute and Eliezer M Van Allen.”

Title: Toward a CRISPR-based mouse model of Vhl-deficient clear cell kidney cancer: Initial experience and lessons learned

Authors: Laura A Stransky, Wenhua Gao, Laura S Schmidt, Kevin Bi, Christopher J Ricketts, Vijyendra Ramesh, Amy James, Simone Difilippantonio, Lilia Ileva, Joseph D Kalen, Baktiar Karim, Albert Jeon, Tamara Morgan, Andrew C Warner, Sevilay Turan, Joanne Unite, Bao Tran, Sulbha Choudhari, Yongmei Zhao, Douglas E Linn, Changhong Yun, Sripriya Dhandapani, Vaishali Parab, Elaine M Pinheiro, Nicole Morris, Lixia He, Sean M Vigeant, Jean-Christophe Pignon, Maura Sticco-Ivins, Sabina Signoretti, Eliezer M Van Allen, W Marston Linehan and William G Kaelin Jr.

Source: Yüksel Ürün/X

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.